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Abstract
Objective—To estimate the lifetime risk of stress incontinence, pelvic organ prolapse surgery, or
both using current, population-based surgical rates from 2007–2011.
Methods—We used a 2007–2011 a U.S. claims and encounters database. We included women
aged 18–89 years and estimated age-specific incidence rates and cumulative incidence (lifetime
risk) of stress incontinence surgery, pelvic organ prolapse surgery, and either incontinence or
prolapse surgery, with 95% confidence intervals. We estimated lifetime risk until the age of 80 to
be consistent with prior studies.
Results—From 2007–2011, we evaluated 10,177,480 adult women who were followed for
24,979,447 person-years. Among these women, we identified 65,397 incident, or first, stress
incontinence, and 57,755 incident prolapse surgeries. Overall, we found that the lifetime risk of
any primary surgery for stress incontinence or pelvic organ prolapse was 20.0% (95%CI 19.9,
20.2) by the age of 80 years. Separately, the cumulative risk for stress incontinence surgery was
13.6% (95%CI 13.5, 13.7) and that for pelvic organ prolapse surgery was 12.6% (95%CI 12.4,
12.7). For age-specific annual risk, stress incontinence demonstrated a bimodal peak at age 46 and
then again at age 70–71 with annual risks of 3.8 and 3.9 per 1,000 women, respectively. For pelvic
organ prolapse, the risk increased progressively until ages 71 and 73 when the annual risk was 4.3
per 1,000 women.
Conclusion—Based on a U.S. claims and encounters database, the estimated lifetime risk of
surgery for either stress incontinence or pelvic organ prolapse in women is 20.0% by the age of
80.
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Stress incontinence and pelvic organ prolapse are highly prevalent conditions(1) which are
often managed surgically. Since the introduction of the tension-free mesh slings in the late
1990’s for incontinence(2) and the subsequent development of vaginal mesh procedures for
pelvic organ prolapse(3), the surgical management of both conditions has increased
substantially.(4, 5)
With these recent changes in surgical practice, an assessment of the lifetime risk of surgery
for stress incontinence and pelvic organ prolapse is necessary to understand the overall
public health impact and burden of pelvic floor disorders. Furthermore, lifetime surgical risk
has critical implications regarding the morbidity associated with surgery (6, 7), the need for
skilled surgeons, and the importance of training future providers. Given that urinary
incontinence and pelvic organ prolapse are more common in the elderly population(1) and
that the U.S. population is aging,(8) a contemporary assessment of lifetime surgical risk is
necessary for accurate projections regarding health care utilization in the coming decades.(9,
10)
A commonly referenced statistic is that a woman has an 11.1% lifetime risk of surgery for
either incontinence or pelvic organ prolapse by the age of 80 years.(11, 12) This estimate
was based on 384 patients who underwent surgery in the Northwest region of the U.S in
1995. The small number of study patients, limited geographic region, and results from two
decades ago potentially limit the applicability of the findings to current surgical practice.
Given the limitations of prior data regarding the lifetime risk of urogynecologic surgery in
the U.S., we sought to use a large, population-based cohort to evaluate the age-specific
incidence of surgery for stress incontinence, pelvic organ prolapse surgery, and either stress
incontinence or prolapse surgery, and to estimate the cumulative risk of surgery over a
woman’s lifetime.
MATERIALS AND METHODS
For this analysis, we utilized 10 years of data (2002–2011) from the MarketScan
Commercial Claims and Encounters database and Medicare Supplemental and Coordination
of Benefits database (copyright © 2012 Truven Health Analytics. All rights reserved).(13,
14) These population-based data included de-identified, adjudicated, healthcare claims from
approximately 150 payers in the U.S. Individuals included in these databases were those
with commercial, employment-based insurance such as employees, their spouses,
dependents, as well as retirees. Claims and enrollment data were validated by Truven Health
Analytics to ensure completeness, accuracy, and reliability. Unique individuals can be
followed over time using encrypted identification numbers, and detailed enrollment data
ensured that only those individuals who could generate a claim were included in the
population at risk at any given time. This database included approximately 53 million
individuals in 2011. Of note, in 2011, 55.1% of the U.S. population, or 170.1 million
individuals, had employment-based insurance; thus, this database includes a significant
proportion of those with employer-based insurance.(15) This study was determined to be
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exempt from further review by the Institutional Review Board at the University of North
Carolina at Chapel Hill as only database contained only de-identified data.
On January 1st of each year from 2007–2011, we identified all women aged 18–89 who were
continuously enrolled for the prior 3 years (look-back period) and the following 12 months
(follow-up period). We excluded women aged older than 89 years because the number of
women and procedures in this age category were low; thus, the data were not very precise
for this age group. We also excluded women who had any surgery for stress incontinence or
pelvic organ prolapse during the 3-year look-back period based on current procedural
terminology (CPT) codes. For stress incontinence we included the following CPT codes:
57288; 51840, 51841, 58152, 51715, 57220, 51845, 57289, 51990, 51992, 58267 or 58293.
For pelvic organ prolapse, we included the following CPT codes: 57200, 57210, 57230,
57240, 57250, 57260, 57265, 57268, 57270, 56810, 57284, 57285, 57423, 57267, 57282,
57283, 57280, 57425, 57106, 57107, 57109, 57110, 57111, 57112, 57120, or 58400. We
also included hysterectomy as a pelvic organ prolapse surgery if there was a primary
diagnosis of prolapse associated with the hysterectomy which occurred on the same date as
surgery. A diagnosis of pelvic organ prolapse was based on the International Classification
of Disease (ICD-9) diagnosis code of 618.x.
Among women who had no stress incontinence or pelvic organ prolapse surgeries during the
look-back period, we identified all incident surgical procedures for stress incontinence and
pelvic organ prolapse during the 12-month follow-up period. We estimated the number of
women who underwent a surgery for stress incontinence, the number with a surgery for
pelvic organ prolapse, and the number of women with any surgery for either stress
incontinence or prolapse during the 12-month follow-up period. In this open cohort study, a
woman could contribute more than one year of age-specific follow-up if she remained
eligible on January 1st of subsequent years.
We estimated age-specific, one-year risks of incident surgery by dividing the number of
women experiencing a surgery during the 12 months of follow-up by the number of eligible
women for each year of age from 18–89. We also estimated the average risk for the
following age groups: 18–29, 30–39, 40–49, 50–59, 60–69, 70–79, and 80–89 years to
facilitate comparison with previously published estimates.(11, 12) We estimated age-
specific surgery rates for stress incontinence only, pelvic organ prolapse only, and either
stress incontinence or prolapse, and reported annual risk per 1,000 women with 95%
confidence intervals (CIs) based on the binomial distribution.(16)
Our primary outcome was the cumulative risk of undergoing either stress incontinence or
pelvic organ prolapse surgery beginning at the age of 18 up to 80 years of age. Because our
objective was to estimate lifetime risk of these surgeries, it was important to account for
death as a competing risk, as not all women live to the age of 80. Age-specific estimates of
all-cause mortality were calculated using national census data and mortality data from the
Centers for Disease Control on U.S. females from 2007.(17, 18) We used the DevCan
software (National Cancer Institute)(16) to estimate the cumulative risk of surgery for stress
incontinence, pelvic organ prolapse, or either with appropriate 95% confidence intervals,
adjusted for the competing risk of death using methods developed by Fay et al.(19, 20)
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For our primary analysis, the identification of incident surgeries during the follow-up period
was based on excluding women who had any history of surgery for either stress
incontinence or pelvic organ prolapse during the prior three years. To assess the sensitivity
of our findings, we repeated the analysis using a five-year look-back period, limiting the
population of eligible women to those who had five years of continuous enrollment and no
stress incontinence or pelvic organ prolapse procedures during that period. While the longer
look-back period increased the likelihood that the surgeries identified during follow-up were
truly incident (rather than repeat) procedures, the trade-off was that fewer women have five
years of continuous enrollment, and thus, our age-specific estimates and ultimately the
estimates of lifetime risk based on these data were less precise.
RESULTS
From 2007–2011, 10,177,480 women 18 to 89 years of age contributed an average of 2.5
years of follow-up for a total of 24,979,447 person-years of follow-up (Table 1). Among
these adult women, there were 65,397 women who had an incident surgery for stress
incontinence, 57,755 women who had an incident surgery for pelvic organ prolapse, and
94,518 women who had an incident procedure for either stress incontinence or prolapse.
The age-specific estimates of the one-year risk of incident surgery for stress incontinence
only, pelvic organ prolapse only, or either incontinence or prolapse for women between the
ages of 18 to 89, are shown in Figure 1. For each decade of age, we also estimated the
average annual risk (Table 2). Because Figure 1 illustrates the one-year risk of incident
surgery for each year of age between 18 and 89, it provides more granularity than the data in
Table 2. For stress incontinence, there were two peaks: first at age 46 when the annual risk
was 3.8 per 1,000 women and then at age 70–71 when the annual risk was 3.9 per 1,000
women. For pelvic organ prolapse, the annual risk increased with age until a peak of 4.3 per
1,000 women at age 71 and 73. For either incontinence or prolapse surgery, the highest risk
was 6.0 per 1,000 women at age 70.
For the primary outcome, we estimated that the lifetime risk for either incontinence or
prolapse surgery was 200.1 per 1,000 women or 20.0% (95% CI 19.9, 20.2) from age 18 to
80 (Figure 2). For surgery for stress incontinence or pelvic organ prolapse surgery, the
lifetime risks were 13.6% (95%CI 13.5, 13.7) and 12.6% (95%CI 12.4, 12.7), respectively.
The previously reported estimate of an 11.1% lifetime risk of either surgery (11) is now
reached by the age of 58, based on the annual risk of surgery during 2007–2011.
We conducted several sensitivity analyses to determine the robustness of our findings. In the
sensitivity analysis using a five-year (rather than three-year) look-back period, the lifetime
risks were slightly lower at 19.8% (95%CI 19.6, 20.0) for either surgery, 13.5 (95%CI 13.3,
13.7) for stress incontinence, and 12.4% (95%CI 12.2, 12.6) for pelvic organ prolapse
surgery. We also conducted a sensitivity analysis in which we did not consider hysterectomy
with a primary diagnosis of pelvic organ prolapse as a qualifying prolapse procedure. The
resulting estimates of lifetime risk of surgery for pelvic organ prolapse were slightly lower
(11.8%, 95%CI: 11.7, 11.9) as were those for the combined risk of surgery for either pelvic
organ prolapse or stress incontinence (19.5%, 95%CI: 19.3, 19.6). We also considered
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whether regional variation in surgical rates would affect our estimates. Weighting the
Marketscan sample to more accurately reflect the geographic distribution of women with
employer-based insurance in the U.S. resulted in estimates of lifetime risk of surgery for
stress incontinence or pelvic organ prolapse that were slightly lower (19.4%).
DISCUSSION
In this contemporary, population-based analysis, we found that the lifetime risk of surgery
for either stress incontinence or pelvic organ prolapse was 20.0%. Thus, in a hypothetical
cohort of women who are currently 18 years of age, one out of every five would be expected
to undergo surgery for either stress incontinence or pelvic organ prolapse by age 80,
highlighting the public health affect of these conditions. For perspective, a woman’s lifetime
risk of developing breast cancer is 14.8%, while the lifetime risk of lung cancer is 6.3%.(21)
Despite the fact that the lifetime risk of stress incontinence and pelvic organ prolapse
surgery is significantly higher than that of breast cancer or lung cancer, women lack
awareness and knowledge regarding these gynecologic conditions,(22, 23) which translates
into limited healthcare seeking for these conditions which greatly impair quality of life.(22,
24)
Our cumulative incidence of 20.0% is nearly double that of two older U.S studies which
reported rates of incontinence and prolapse surgery of 11.1%(11) and 11.8%.(12) We
believe that this may be attributable to several different factors. First, the introduction of
new surgical techniques, namely mid-urethral synthetic slings and transvaginal mesh
procedures for pelvic organ prolapse, have resulted in higher rates of stress incontinence(4)
and mesh prolapse surgeries.(5) For example, the rate of sling procedures increased from
209.7 to 266.5 per 100,000 person years from 2000 to 2009,(4) and the rate of vaginal mesh
procedures increased from a rate of 36.7 to 60.8 per 100,000 person years from 2005 to
2010.(5) These products potentially allowed more gynecologists to offer pelvic floor repair
based on a perception of improved ease and efficiency. In addition, the regional variation in
stress incontinence and pelvic organ prolapse surgery in the U.S. may contribute, with
higher rates in the South and the Midwest compared to the Northeast and West.(4, 5) Both
of the prior studies were based in the Northwest,(11, 12) which may have underestimated
the overall lifetime risk of surgery. Finally, previous investigations did not report confidence
intervals around the cumulative risk, and with significantly smaller sample sizes, these
estimates were likely less precise.
Estimated lifetime incidence rates of pelvic floor surgeries in other countries vary. In the
Netherlands, de Boer et al.(25) reported a 20.3% risk of prior surgery in women aged 76–85
years. Among parous women in United Kingdom, Abdel-Fattah et al. found a 12.2% lifetime
risk of incontinence and pelvic organ prolapse surgery.(26) A cross-sectional study from
Australia reported a rate of 19% for pelvic organ prolapse surgery, which is significantly
higher than our rate of 12.6%.(27) This international variance could be explained by true
global differences in disease prevalence or differences in surgical practice patterns. For
accurate public health planning, it is helpful to have current estimates of surgical rates that
are reflective of national practice.
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Regarding age-specific incidence, our study showed similar trends to prior studies with the
highest rates of surgery in women aged 70–79.(11, 12) Our annual risk of surgery for either
incontinence or pelvic organ prolapse surgery in this age group was 5.3 per 1,000 women
(95% CI 5.2, 5.4) compared to 3.70 per 1,000 person-years from Fialkow et al.(12) and 6.62
per 1,000 person-years from Olsen et al.(11) By evaluating incident surgery rates by age in
decades, some of the details regarding the impact of age may not be evident. In our study,
we were able to provide insight into how stress incontinence surgery rates change with
yearly increases in age, and we found two peaks in incidence around age 46 and 70–71
years. For pelvic organ prolapse, we found that our highest annual risk of incident surgery
was 4.3 per 1,000 women at 71 and 73 years, and Smith et al. also noted the highest rate
among 65–69 year olds from 2001–2005 with a rate of 5.0 per 1,000 person-years (95% CI
4.7, 5.4).(27)
The strengths of this study include the large, population-based cohort of over 10 million
women that reflects practice patterns across the entire country during recent years. This is in
contrast to prior U.S. studies which utilized data from almost two decades ago, focused on a
single region, evaluated substantially smaller cohorts, and did not estimate confidence
intervals. Our estimates of lifetime risk are based on the surgery rates between 2007 and
2011, which reflect practice since the introduction of mesh procedures for incontinence and
pelvic organ prolapse.(4, 5) The magnitude of data allowed for calculation of incidence rates
at every year of age, permitting a more accurate estimation of cumulative incidence. We also
estimated confidence intervals to provide a sense of the precision of our age-specific and
cumulative incidence estimates. Lastly, a novel aspect of our study is that we accounted for
competing risks of mortality, and we utilized rigorous, state-of-the-art methodology
developed and utilized by the National Cancer Institute to estimate lifetime risk of different
types of cancer.(16, 19, 20)
Our study also had several limitations. While healthcare claims data provide an enormous
number of subjects and procedures to evaluate, they do not permit a review of past medical
records, and we are limited to the data included in healthcare claims. For example, we were
unable to evaluate race, body mass index and comorbidities, such as obesity, diabetes or
smoking with accuracy. Furthermore, we were limited our ability to definitively exclude
women with prior surgeries; however, our estimates did not change significantly when we
conducted a sensitivity analysis with a longer look-back period. For pelvic organ prolapse
surgeries, we included hysterectomies with a primary diagnosis of prolapse. It is possible
that uterine prolapse may be used as a billable diagnosis to perform a hysterectomy for a
non-billable reason, such as contraception, and thus, might result in an over-estimation of
the use of hysterectomy for symptomatic prolapse. These procedures represented 6.4% of
incident procedures for pelvic organ prolapse and excluding them from the analysis had a
modest effect on the estimates of lifetime risk. Our rationale for including hysterectomies
was that women with uterovaginal prolapse are commonly undertreated by a hysterectomy
alone as they do not undergo any concomitant prolapse surgeries. A study of California
discharge data found that only 35% of women who underwent a hysterectomy for a primary
diagnosis of uterovaginal prolapse had a concomitant apical support procedure.(28) Our
study population was comprised of individuals with employer-based insurance or those with
supplemental insurance from their employer or retirement benefit once they transition into
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Medicare. We were not able to evaluate the uninsured or those on Medicaid, a population
who may have different surgery rates. That said, the majority of Americans (55%) have
employment-based insurance so these estimates represent a substantial portion of the US
population.(15)
Based on surgery rates from 2007–2011, the lifetime risk of undergoing a stress
incontinence or pelvic organ prolapse surgery by the age of 80 is 20.0%. These surgeries
will place a growing demand on health care resources and will require a commensurate
increase in the number of trained pelvic floor surgeons. The high rates of surgery for both
stress incontinence and pelvic organ prolapse continue to expose the need for improved
prevention strategies.
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Age-specific annual risk (per 1,000 women) of surgery for stress urinary incontinence (SUI),
pelvic organ prolapse (POP), or either SUI or POP surgery with 95% confidence intervals
(CI).
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Cumulative incidence, or lifetime risk, of surgery for stress urinary incontinence (SUI),
pelvic organ prolapse (POP), or SUI or POP surgery from age 18 years through age 84
years. The width of the lines represents the 95% confidence interval (CI) of the cumulative
incidence at each age. The cumulative incidence (95% CI) by age 80 per 1,000 women was
200.1 (95% CI 198.7–201.5) for SUI or POP, 135.9 (95%CI 134.8–137.1) for SUI only, and
125.6 (95% CI 124.4–126.7) for POP only.
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TABLE 1
Study Population Who Had One-Year of Continuous Follow-Up and Who Did Not Have a Stress Incontinence
or Pelvic Organ Prolapse Procedure During the Prior 3 Years
Characteristic Person-Years % of Total Person-Years
Age
 18–29 2,987,244 12.0
 30–39 3,642,368 14.6
 40–49 5,278,482 21.1
 50–59 6,306,039 25.2
 60–69 3,720,152 14.9
 70–79 1,876,460 7.5
 80–89 1,168,702 4.7
Region
 Northeast 2,606,670 10.4
 North Central 6,837,698 27.4
 South 10,776,805 43.1
 West 4,695,963 18.8
 Unknown 62,311 0.3
Year
 2007 3,418,269 13.7
 2008 4,192,798 16.8
 2009 5,755,982 23.0
 2010 5,153,437 20.6
 2011 6,458,961 25.9
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